Physicochemical and immunological effects of adjuvant formulations with snake venom antigens for immunization of horses for antivenom production.
Adjuvant formulation
Adjuvant-antigen compatibility
Antivenom
Horse immunization
Snake venom
Snakebite
Journal
Toxicon : official journal of the International Society on Toxinology
ISSN: 1879-3150
Titre abrégé: Toxicon
Pays: England
ID NLM: 1307333
Informations de publication
Date de publication:
15 Aug 2023
15 Aug 2023
Historique:
received:
18
05
2023
revised:
19
07
2023
accepted:
21
07
2023
medline:
8
8
2023
pubmed:
27
7
2023
entrez:
26
7
2023
Statut:
ppublish
Résumé
Enhancement of antivenom immune responses in horses through adjuvant technology improves antivenom production efficiency, but substantial local reactogenicity associated with some traditional veterinary adjuvants limits their usability. To explore modern adjuvant systems suitable for generating antivenom responses in horses, we first assessed their physicochemical compatibility with Bothrops asper snake venom. Liposome and nanoparticle aluminum adjuvants exhibited changes in particle size and phospholipid content after mixing with venom, whereas squalene emulsion-based adjuvants remained stable. Next, we evaluated serum antibody response magnitude and neutralization capacity in horses immunized with adjuvant-containing Echis ocellatus, Bitis arietans, Naja nigricollis, and Dendroaspis polylepis venom preparations. Whereas all tested adjuvants elicited significant neutralization capacity against the viperid venoms, the greatest antibody responses were generated by a squalene-in-water emulsion, thus representing a promising novel alternative for antivenom production.
Identifiants
pubmed: 37495191
pii: S0041-0101(23)00215-5
doi: 10.1016/j.toxicon.2023.107229
pii:
doi:
Substances chimiques
Antivenins
0
Emulsions
0
Squalene
7QWM220FJH
Snake Venoms
0
Adjuvants, Immunologic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107229Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests. CBF and APK are inventors on patents and/or patent applications involving adjuvant formulations and methods featured here. All other authors declare they have no competing interests.